Lupin Limited Patent applications |
Patent application number | Title | Published |
20160136141 | RIFAXIMIN READY-TO-USE SUSPENSION - A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension. | 05-19-2016 |
20160107990 | 4-(5-(4-CHLOROPHENYL)-2-(2-CYCLOPROPYLACETYL)-1,4-DIMETHYL-1H-PYRROL-3-YL)- BENZENESULFONAMIDE AS ALPHA 7 NACHR MODULATOR - Disclosed are an alpha 7 nAChR receptor modulator compound, 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yljbenzenesulfonamide, its tautomeric form, its pharmaceutically acceptable salts, pharmaceutical compositions comprising the compound or a salt thereof, and a method of treating various diseases, disorders or conditions, for example, Alzheimer's disease, mild cognitive impairment, senile dementia, vascular dementia, dementia of Parkinson's disease, and attention deficit disorder. | 04-21-2016 |
20150361041 | Pyrrole Derivatives as Alpha 7 NACHR Modulators - Disclosed is a compound of formula (I), wherein R | 12-17-2015 |
20150344422 | Pyrrole Derivatives as Alpha 7 NACHR Modulators - Disclosed are compounds of the Formula (I), wherein R | 12-03-2015 |
20150299186 | HETEROCYCLYL COMPOUNDS - The present invention is related to heteroaryl compounds as MEK inhibitors. The invention includes heteroaryl compounds of formula I, their tautomers and pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them. | 10-22-2015 |
20150299178 | Thiazole Derivatives as Alpha 7 NACHR Modulators - Disclosed is a compound of formula (I), wherein R | 10-22-2015 |
20150291617 | Thiazole Derivatives as Alpha 7 nAChR Modulators - Disclosed is a compound of formula (I) wherein Y, Ring D, m and R | 10-15-2015 |
20150231143 | Heteroaryl Derivatives as Alpha7 NACHR Modulators - Disclosed is a compound of formula I: | 08-20-2015 |
20150225380 | Novel Method to Obtain Olmesartan Medoxomil With Reduced Particle Size - The present invention provides a novel method to obtain olmesartan medoxomil (I) with a particle size distribution of less than 30 μm comprising: dissolving olmesartan medoxomil (I) in a solvent; adding seed crystals of olmesartan medoxomil (I), followed by isolation. | 08-13-2015 |
20150209432 | PHARMACEUTICAL COMPOSITIONS OF PROTON PUMP INHIBITOR - The present invention relates to pharmaceutical compositions of Proton Pump Inhibitor and process for preparation of such composition thereof. The invention relates to pharmaceutical compositions comprising Proton Pump Inhibitor, crospovidone, basic inorganic salt and one or more pharmaceutically acceptable excipients. The present invention provides stable pharmaceutical compositions of Dexlansoprazole which are bioequivalent to marketed dual delayed release pharmaceutical compositions of Dexlansoprazole. | 07-30-2015 |
20150152118 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors - Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R | 06-04-2015 |
20150010505 | Antiviral Compounds with a Dibenzooxaheterocycle Moiety - Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R-R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds. (I). | 01-08-2015 |
20150010504 | Antiviral Compounds with a Heterotricycle Moiety - Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R | 01-08-2015 |
20140357871 | PROCESS FOR PREPARATION OF RUFINAMIDE - The present invention relates to a novel process for preparation of rufinamide (I) comprising: reacting 2,6-difluorobenzyl azide (II) and propiolic acid (III) in a mixture of alcohol and water to produce 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid (IV), esterifying the acid (IV) to ester (V) and treating ester (V) with ammonia. The invention further relates to process for purification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid (IV), by crystallization from a mixture of alcohol and water. The present invention also provides process for purification of rufinamide (I) by crystallization from mixture of polar aprotic solvent with water or alcohol. | 12-04-2014 |
20140315871 | TOPICAL PHARMACEUTICAL COMPOSITIONS OF ANTI-MICROBIAL AGENTS AND ANTI-INFLAMMATORY AGENTS - The present invention provides sterile, storage-stable topical pharmaceutical compositions intended for application to the eye, ear or nose comprising Dexamethsone and Ciprofloxacin. The topical pharmaceutical compositions of invention comprises combination of ionic tonicity agent and non-ionic tonicity agent(s). The topical pharmaceutical compositions further comprises boric acid. The invention provides a process for preparing and sterilizing the compositions in order to reduce the amount of related compounds and impurities associated with the topical compositions on storage. The topical pharmaceutical compositions of invention found storage-stable, have easy resuspendability. | 10-23-2014 |
20140256959 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES - The present invention relates to fosamprenavir calcium (Ia) substantially free of isomer impurity, (3R) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propyl carbamate (Ib), and its process for preparation thereof. The present invention also provides fosamprenavir calcium intermediate, (S)-3-tetrahydrofuranyl-N-succinimidyl carbonate (IIa) substantially free of (R)-3-tetrahydrofuranylsuccinimidyl carbonate (IIb) and its process for preparation thereof. | 09-11-2014 |
20140221414 | SOLID DISPERSION OF RIFAXIMIN - A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin. | 08-07-2014 |
20140179930 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL - The present invention provides novel process for preparation of olmesartan medoxomil (I) substantially free of olmesartan acid impurity (II) comprising, reacting trityl olmesartan medoxomil (III) with acid, filtering the precipitate of trityl alcohol, subjecting the filtrate to agitated thin film drying and recovering olmesartan medoxomil (I). | 06-26-2014 |
20140155607 | Novel Salts of Raltegravir - The present invention provides novel salts of raltegravir, viz., meglumine salt, erbumine salt, ammonium salt, tris salt and L-arginine salt of raltegravir and processes for their preparation. | 06-05-2014 |
20140155433 | BIARYL DERIVATIVES AS NACHR MODULATORS - Disclosed is a compound of formula (I): wherein ‘D’, ‘E’, ‘m’, ‘n’ and R | 06-05-2014 |
20140066638 | NOVEL PROCESS FOR PREPARATION OF DARUNAVIR AND DARUNAVIR ETHANOLATE OF FINE PARTICLE SIZE - The present invention provides a novel process for preparation of darunavir that involves reduction of [(1S,2R)-3-[[(4-nitrophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, of formula (5). The present invention also provides darunavir ethanolate of particle size wherein d | 03-06-2014 |
20140018358 | BENZO [B] [1,4] OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS - Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors of Formula (I). | 01-16-2014 |
20140018327 | Pyrrole Derivatives as Nicotinic Acetylcholine Receptor Modulators for Use in the Treatment of Neurodegenerative Disorders Such as Alzheimer's and Parkinson's Disease - Disclosed is a compound of formula (I) wherein ‘a’ and R | 01-16-2014 |
20130345213 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR - Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors of Formula (I). | 12-26-2013 |
20130331387 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS - Disclosed is a compound of formula (I), wherein Z, m and R | 12-12-2013 |
20130324748 | PROCESS FOR PREPARATION OF LEVONORGESTREL - The present invention provides an improved process for preparation of levonorgestrel (3) which comprises of hydrolysis of 13β-ethyl-3-methoxy-17α-ethynyl-gona-2,5(10)-dien-17β-ol (2) with an acid in aprotic solvent. The present invention also provides a novel process for purification of crude levonorgestrel (3) by recrystallization from N,N-dimethyl formamide-water; methanol-water mixture. | 12-05-2013 |
20130323309 | Sustained Release Composition of Memantine - A sustained release pharmaceutical composition comprising; a core including memantine or its pharmaceutically acceptable salts and one or more pharmaceutical acceptable excipients, and a sustained release coating comprising a water insoluble substance and a water soluble substance where the ratio of the water insoluble substance to the water soluble substance is from about 1:0 to about 3:5:1, optionally containing an immediate release coating having memantine where the immediate release coating is applied over the sustained release coating. | 12-05-2013 |
20130317063 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BEPOTASTINE - The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria. | 11-28-2013 |
20130310419 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR - The present invention is related to pyrrole derivatives of formula I as the modulators of nicotinic acetylcholine receptors particularly the α7 subtype. The invention includes pyrrole derivatives, analogues, their prodrugs, their isotopes, their metabolites, pharmaceutically acceptable salts, polymorphs, solvates, optical isomers, clathrates, co-crystals, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them. Owing to the modulatory activity of the pyrrole derivatives on the nicotinic acetylcholine receptors, the invention finds application in the prophylaxis and therapy of disorders encompassing the involvement of cholinergic transmission in the central and peripheral nervous system. The invention relates to the ability of pyrrole derivatives to modulate the cholinergic transmission and efficacy of the endogenous neurotransmitter ACh thorough the nicotinic acetylcholine receptors particularly the α7 subtype. | 11-21-2013 |
20130296562 | STEREOSELECTIVE PROCESS FOR PREPARATION OF 1,3-OXATHIOLANE NUCLEOSIDES - The present invention relates to a stereoselective glycosylation for the preparation of 1,3-oxathiolane nucleoside in high yield and high optical purity. The invention specifically relates to a process of the preparation of Lamivudine and Emtricitabine using zirconium (IV) chloride (ZrCl | 11-07-2013 |
20130245000 | BICYCLIC GPR119 MODULATORS - The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR119 receptor by using either alone or in combinations of Formula (I). | 09-19-2013 |
20130225845 | PROCESS FOR PREPARATION OF ESTRADIOL VALERATE AND A NOVEL CRYSTALLINE FORM A OF ESTRADIOL DIVALERATE - The present invention relates to the process for the preparation of estradiol valerate (I) which involves isolation of crystalline estradiol divalerate (III) by crystallization from an alcoholic solvent. | 08-29-2013 |
20130225600 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS - The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I). | 08-29-2013 |
20130213828 | DESICCANT CONTAINER - The present application relates to a container for storing tablets and/or capsules. The container may include an upper portion and a bottom portion which defines an integrated chamber, rib profile and a separator means snap-locked in the rib profile. The separator means may include perforated disc means. | 08-22-2013 |
20130203721 | TASTE-MASKED POWDER FOR SUSPENSION COMPOSITIONS OF METHYLPREDNISOLONE - A dry taste masked powder composition comprising a steroid or its salts or derivatives and pharmaceutically acceptable excipients. The taste-masked powder may be used for suspension compositions suitable for use as a liquid suspension for children and elderly patients. | 08-08-2013 |
20130178457 | CANNABINOID RECEPTOR MODULATORS - Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I). | 07-11-2013 |
20130174651 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES - The present invention relates to fosamprenavir calcium (Ia) substantially free of isomer impurity, (3R) tetrahydro -3 -furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propyl carbamate (Ib), and its process for preparation thereof. The present invention also provides fosamprenavir calcium intermediate, (S)-3-tetrahydrofuranyl-N-succinimidyl carbonate (IIa) substantially free of (R)-3-tetrahydrofuranylsuccinimidyl carbonate (IIb) and its process for preparation thereof. | 07-11-2013 |
20130156854 | Controlled Release Pharmaceutical Compositions of Milnacipran - A controlled release pharmaceutical compositions comprising Milnacipran or pharmaceutically acceptable salts there—of is provided. The pharmaceutical composition comprises an immediate release core comprising Milnacipran or pharmaceutically acceptable salts thereof, pharmaceutically acceptable excipients and a coating on the immediate release core comprising rate controlling agents. | 06-20-2013 |
20130143897 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BLONANSERIN - An oral controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) and optionally pharmaceutically acceptable excipients is provided. The present invention further relates to a controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) such that the composition releases not less than about 80% of Blonanserin within 20 hours, when dissolution is carried out in 900 ml, 0.1 N HCl, USP apparatus Type II (Paddle) at 50 rpm for 20 hrs. The controlled release pharmaceutical composition of the invention releases 50% of Blonanserin between about 4 to 14 hours, when dissolution is carried out in 900 ml, 0.1 N HCl, USP apparatus Type II (Paddle) at 50 rpm. | 06-06-2013 |
20130143857 | PHARMACEUTICAL COMPOSITIONS OF CEFDITOREN PIVOXIL - The present invention relates to a pharmaceutical composition comprising Cefditoren pivoxil, water soluble high molecular weight substance and one or more pharmaceutically acceptable excipient wherein weight ratio of high molecular weight substance to Cefditoren pivoxil is greater than 1:4 and a process for preparation thereof. | 06-06-2013 |
20130142849 | CONTROLLED RELEASE FORMULATIONS OF DRONEDARONE - The present invention relates to controlled release formulation of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of controlled release formulations of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day. | 06-06-2013 |
20130122542 | MODIFIED SAK GENE FOR THE PRODUCTION OF RECOMBINANT PROTEINS - The present invention relates to modified SAK gene having amino acid SEQ ID 2. The present invention further relates to process for cloning and expressing modified SAK gene fusion protein which imparts improved stability to the heterologous protein of interest. Further the invention relates to process of purification of recombinant heterologous proteins from bacterial inclusion bodies using modified SAK. | 05-16-2013 |
20130122090 | Multiple Unit Tablet Composition - A multiple unit tablet composition comprising an enteric coated multiple unit cores comprising a pharmaceutically active ingredient, wherein plasticizer content of enteric coating is less than about 10% by weight of the enteric coating polymer; at least two diluents and optionally one or more other pharmaceutically acceptable excipient, wherein one diluent is highly compactable microcrystalline cellulose and process for preparing the same. | 05-16-2013 |
20130096319 | PROCESS FOR PREPARATION OF AMISULPRIDE - The present invention is related to a novel process for the preparation of amisulpride (I) which involves: methylation of 4-amino-salicylic-acid (VI) with dimethyl sulphate and base, optionally in presence of TBAB to obtain 4-amino-2-methoxy methyl benzoate (VII) and (ii) oxidation of 4-amino-2-methoxy-5-ethyl thio benzoic acid (IX) or 4-amino-2-methoxy-5-ethyl thio methyl benzoate (X) with oxidizing agent in the presence of sodium tungstate or ammonium molybdate to give 2-methoxy-4-amino-5-ethyl-sulfonyl benzoic acid (IV) or 2-methoxy-4-amino-5-ethyl-sulfonyl methyl benzoate (XI) respectively. | 04-18-2013 |
20130041166 | PROCESS FOR THE PREPARATION OF DIENOGEST SUBSTANTIALLY FREE OF IMPURITIES - The present invention provides novel process for preparation and purification of dienogest (I). The present invention provides dienogest (I) substantially free of impurities. | 02-14-2013 |
20130039957 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BRIVARACETAM - The present invention relates to controlled release pharmaceutical compositions comprising Brivaracetam or its pharmaceutically acceptable derivatives thereof. Further disclosed is a controlled release pharmaceutical composition comprising a core and a coating surrounding the core, wherein the core comprises Brivaracetam or pharmaceutically acceptable derivative thereof and the coating comprises hydrophobic release controlling agent. The controlled release pharmaceutical composition comprises Brivaracetam or pharmaceutically acceptable derivatives thereof and hydrophobic release controlling agent, wherein said composition has dissolution of Brivaracetam at least 80% between about 7 to about 24 hours when measured in 900 ml of pH 6 phosphate buffer solution using USP apparatus type II, at 50 rpm and at 37° C. Also disclosed is a controlled release pharmaceutical composition useful for the treatment of epilepsy and treatment of symptomatic myoclonus comprises Brivaracetam or pharmaceutically acceptable derivative thereof and hydrophobic release controlling agent. | 02-14-2013 |
20130022654 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF TAPENTADOL - A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean T | 01-24-2013 |
20130005780 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF TAPENTADOL - The present invention provides atazanavir sulfate substantially free of diastereomeric impurities. The present invention also provides atazanavir sulfate having D-tertiary leucine analogues less than 0.1%. The present invention further relates to an improved process for preparing atazanavir sulfate, substantially free of its diastereoisomeric impurities, which comprises of reacting diamino compound (IV) with N-methoxycarbonyl-(L)-tertiary-leucine (V) having D-isomer less than 0.1% to obtain atazanavir base; conversion of atazanavir base to atazanavir sulfate by reacting with sulfuric acid and crystallization of atazanavir sulfate from suitable organic solvent(s). | 01-03-2013 |
20130004545 | SLOW RELEASE PHARMACEUTICAL COMPOSITIONS OF ILOPERIDONE - A slow release pharmaceutical composition comprising iloperidone or its active metabolites and a slow release agent is described. Also disclosed is slow release pharmaceutical composition comprising iloperidone or its active metabolites, wherein the slow release composition is a combination of a controlled release composition and an immediate release composition. | 01-03-2013 |
20120316361 | METHOD OF RESOLUTION OF (RS)- 1,1'-BI-2-NAPHTHOL FOR OBTAINING ENANTIOMERIC PURE I.E. (S)-(-)-1,1'-BI-2-NAPHTHOL AND/OR (R)-(+)-1,1'-BI-2-NAPHTHOL VIA CO-CRYSTAL FORMATION WITH OPTICALLY ACTIVE DERIVATIVES OF y -AMINO ACIDS - Novel method for synthesis of optically pure (S)-(−)-1,1′-bi-2-naphthol and/or (R)-(+)-1,1′-bi-2-naphthol via resolution of racemic (RS)-1,1′-bi-2-naphthol through formation of co-crystal with optically active derivatives of γ-amino acids. | 12-13-2012 |
20120316238 | NOVEL POLYMOMORPH OF DESVENLAFAXINE BENZOATE - The present invention relates to a novel crystalline form L of (±)-desvenlafaxine benzoate and process for the preparing of the same. Further, the present invention also relates to pharmaceutical composition of novel crystalline form L of desvenlafaxine benzoate and one or more pharmaceutically acceptable excipient. | 12-13-2012 |
20120283252 | PROCESS FOR PREPARING PHARMACEUTICAL OPHTHALMIC COMPOSITIONS - Pharmaceutical ophthalmic compositions comprising active ingredient(s) such as carbonic anhydrase inhibitor (CAI) or combinations and processes for making such compositions and the use of these compositions in patient populations including pediatric populations. A process for preparing an ophthalmic composition comprising a carbonic anhydrase inhibitor, which comprises a) preparing a slurry comprising a carbonic anhydrase inhibitor and a surfactant; b) preparing a polymer slurry comprising a polymer and water; c) preparing a solution comprising tonicity and preservative agents; d) mixing the polymer slurry of step b and the solution of step c, to form a vehicle concentrate and adjusting pH; e) adding the slurry of step a, to the vehicle concentrate of step d and mixing to homogenize; f) autoclaving the mixture of step e; g) sizing the mixture of step f, under aseptic condition. | 11-08-2012 |
20120237770 | NOVEL PROCESS FOR PREPARATION OF DARUNAVIR AND DARUNAVIR ETHANOLATE OF FINE PARTICLE SIZE - The present invention provides a novel process for preparation of darunavir that involves reduction of [(1S,2R)-3-[[(4-nitrophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy -1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, of formula (5). The present invention also provides darunavir ethanolate of particle size wherein d | 09-20-2012 |
20120219631 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE - The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal C | 08-30-2012 |
20120214833 | SOLID DISPERSION OF RIFAXIMIN - A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin. | 08-23-2012 |
20120203004 | PROCESS FOR THE SYNTHESIS OF ALKYL/ARALKYL (2S)-2-(TERT-BUTOXYCARBONYL)-AMINO-2-[-8-AZABICYCLO[3.2.1]OCT-3-YL]-EXO-A- CETATE AND ANALOGS THEREOF: KEY INTERMEDIATES FOR THE PREPARATION OF DPPIV INHIBITORS - An improved process for the synthesis of intermediates like Alkyl/Aralkyl (2S)-2-(tert-butoxycarbonyl)-amino-2-[-8-azabicyclo[3.2.1]oct-3-yl]-exo-acetate and analogs thereof which are useful in the synthesis of Dipeptidyl peptidase-IV (DP-PIV) inhibitors. | 08-09-2012 |
20120177729 | SUSTAINED RELEASE COMPOSITION OF RANOLAZINE - The present invention relates to sustained release dosage form of Ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof which comprises a combination of at least two pH-dependent binders and optionally one or more pharmaceutically acceptable excipient(s). | 07-12-2012 |
20120128772 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF MILNACIPRAN - A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90% of the total amount of Milnacipran or pharmaceutically acceptable salts thereof between 8 to 20 hours when dissolution is carried out in 900 ml 0.1N HCl, USP apparatus Type I (Basket) at 100 rpm for 2 hrs, followed by 900 ml Phosphate buffer pH 6.8 USP apparatus Type I (Basket) at 100 rpm. A process of preparing a controlled release pharmaceutical composition comprises: a) preparing a first layer comprising i) melting hydrophobic release controlling agent and Milnacipran or pharmaceutically acceptable salts thereof in it ii) cooling followed by sieving the melted mass to obtain granules and iii) lubricating the granules; and b) preparing a second layer comprising granules which comprises hydrophobic release controlling agent and optionally Milnacipran or pharmaceutically acceptable salts thereof | 05-24-2012 |
20120108809 | PROCESS FOR PREPARATION OF EFAVIRENZ - An improved process for Efavirenz, which has several advantages over reported methods like low cost, high yield, better optical purity and industrial feasibility. | 05-03-2012 |
20120107876 | NOVEL FUSION TAG OFFERING SOLUBILITY TO INSOLUBLE RECOMBINANT PROTEIN - The invention relates to a fusion tag comprising Serine-aspartic acid repeats of the well conserved region of the | 05-03-2012 |
20120093765 | PROCESS FOR PURIFICATION OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR - The present invention describes a novel process for large-scale purification of therapeutic grade quality of recombinant human GCSF from microbial cells, wherein the protein is expressed as inclusion bodies. The Inclusion bodies are solubilized and refolded under redox condition. The Redox condition is provided by using ascorbic acid, dehydroascorbic acid and reduced gluthathione. The process involves the novel use of aqueous two phase extraction step to purify refolded GCSF after removal of denaturant. After this step GCSF is further purified using chromatography techniques for removal of related impurities. The GCSF obtained has good purity and yields which are essential for a production scale process. The host cell related contaminants like proteins, DNA and endotoxins are reduced using the purification processes of the invention. | 04-19-2012 |
20120082635 | 2-AMINO-2- [8-(DIMETHYL CARBAMOYL)- 8-AZA- BICYCLO [3.2.1] OCT-3-YL]-EXO- ETHANOYL DERIVATIVES AS POTENT DPP-IV INHIBITORS - The present invention is related to novel 2-Amino-2-[8-(dimethyl carbamoyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-exo-ethanoyl derivatives of the general formula (A), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved. | 04-05-2012 |
20120077817 | NOVEL PHARMACEUTICAL COMPOSITIONS OF RANOLAZINE - A novel controlled release pharmaceutical dosage form comprising a therapeutically effective amount of ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof, one or more lipid(s) as release controlling agent(s) and one or more pharmaceutically acceptable excipient(s). | 03-29-2012 |
20120027855 | PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY - The present invention relates to controlled release pharmaceutical formulations of active principle(s) like tetracycline-class antibiotics for providing increased residence time in the gastrointestinal tract and the process of preparing them. | 02-02-2012 |
20110301139 | PHARMACEUTICAL COMPOSITIONS OF CEFIXIME - A pharmaceutical suspension dosage form comprising greater than 80 mg/ml and not more than 150 mg/ml of Cefixime and pharmaceutically acceptable excipients. | 12-08-2011 |
20110288298 | NOVEL POLYMORPH OF EMTRICITABINE AND A PROCESS FOR PREPARING OF THE SAME - A polymorph of emtricitabine, wherein said polymorph displays angular positions of characteristic peaks in powder X-ray diffraction pattern 13.61±0.2, 15.54±0.2, 19.49±0.2, 20.55±0.2, 25.89±0.2, 28.09±0.2 and 29.10±0.2. A pharmaceutical composition comprising a polymorph of emtricitabine displaying angular positions of characteristic peaks in powder X-ray diffraction pattern 13.61±0.2, 15.54±0.2, 19.49±0.2, 20.55±0.2, 25.89±0.2, 28.09±0.2 and 29.10±0.2. A process for the preparation of a polymorph of emtricitabine comprising the steps of (a) dissolving crude emtricitabine in polar organic solvent by heating at a temperature of at least 40° C. and not more than 150° C. to form a reaction mixture optionally decreasing the concentration of polar organic solvent in said reaction mixture; cooling the reaction mixture obtained in step (a); and separating the solid from the cooled reaction mixture resulted in step (b). | 11-24-2011 |
20110257396 | PROCESS FOR THE MANUFACTURE OF CIS(-)-LAMIVUDINE - An improved process for the manufacture of Lamivudine. The process involves: | 10-20-2011 |
20110195117 | CONTROLLED RELEASE COMPOSITIONS OF ROPINIROLE - A novel oral controlled release pharmaceutical composition comprising a therapeutically effective amount of active substance, ropinirole or a pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) or hydrate(s) thereof, one or more controlled release agent(s), optionally one or more pharmaceutically acceptable excipient(s) and an extended release coating, wherein the said composition provides controlled release of the active agent with reduced initial burst release. | 08-11-2011 |
20110165583 | VECTOR FOR IDENTIFICATION, SELECTION AND EXPRESSION OF RECOMBINANTS - A modified vector comprising a reporter gene having a STOP codon upstream of the multiple cloning site of the vector which is characterized in that the recombinant clones show fluoresce or show color in presence of inducer. A method for identification and selection of recombinant clones comprising the modified vector wherein the recombinant clones florescence or show color in a suitable suppressor strain of the STOP codon associated with the gene of interest. A method of preparation of recombinant clone comprising gene of interest and modified vector comprising amplification of gene of interest using specific primers containing STOP codon different from STOP codon used with reporter gene; cloning the amplified gene of interest in the modified vector; transformation of cloned modified vector in the STOP codon suppressor host cell wherein the STOP codon suppressor host cell is specific for STOP codon used with the gene of interest wherein the recombinant clones either fluorescence or show color depending upon the reporter gene used. | 07-07-2011 |
20110151002 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING QUETIAPINE - A sustained release dosage form comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more non-gellable release controlling polymer and one or more pharmaceutically acceptable excipient(s). A sustained release dosage form comprising first granulation comprising Quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof and one or more release controlling material; and second granulation comprising one or more release controlling material which is the same or different than the one or more release controlling material of the first granulation and optionally quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof. A method of preparing the sustained release dosage form by first and second granulation followed by milling; blending the said milled granules after second granulation with lubricant followed by compression to form a sustained release dosage form. A sustained release dosage form comprising immediate release core comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more pharmaceutically acceptable excipients; and sustained release coating comprising one or more non-gellable release controlling material. | 06-23-2011 |
20110124879 | STABLE AMORPHOUS FORM OF CARVEDILOL DIHYDROGEN PHOSPHATE WITH STABILIZER - The present invention provides a novel stable amorphous form of carvedilol dihydrogen phosphate and the process for its preparation that involves reaction of carvedilol base with ortho phosphoric acid in the presence of stabilizer in a suitable solvent or mixture of solvents followed by concentration and isolation. An alternate process for preparation of amorphous form of carvedilol dihydrogen phosphate involves addition of stabiliser to the solution of stable amorphous or crystalline carvedilol dihydrogen phosphate in a suitable solvent or mixture of solvents followed by concentration and isolation. The novel stable amorphous form of carvedilol dihydrogen phosphate is highly stable. | 05-26-2011 |
20110028660 | PROCESS FOR THE PREPARATION OF CROSS-LINKED POLYALLYLAMINE POLYMER - A process for the polymerization of allylamine and its subsequent crosslinking in the presence of a dispersing agent. | 02-03-2011 |
20110003837 | MODIFIED RELEASE FORMULATIONS OF HMG COA REDUCTASE INHIBITORS - Modified release formulations of HMG Co-A reductase inhibitors, which provide reduced incidence of rhabdomyolysis, renal toxicity and other side effects by increasing hepatic bioavailability and decreasing systemic availability upon oral administration. The modified release pharmaceutical formulation comprises a therapeutically effective amount of HMG CoA reductase inhibitor or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), prodrug or metabolite thereof, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein the modified release formulation provides reduced incidence of adverse effects and improved efficacy when compared to the immediate release formulation upon oral administration. | 01-06-2011 |
20100291020 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS - The present invention is related to novel compounds of the general formula A, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved. | 11-18-2010 |
20100272801 | PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND VALSARTAN - A single layer pharmaceutical composition comprising active agent(s) amlodipine or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof wherein the composition exhibits bioequivalence to the commercially available bilayer tablet dosage form comprising amlodipine besylate and valsartan; when administered to human subject, under the bioequivalence parameters of a 90% Confidence Interval for AUC which is between 80% and 125%, and a 90% Confidence Interval for Cmax, which is between 80% and 125%. | 10-28-2010 |
20100255067 | Controlled Release Pharmaceutical Compositions of Pregabalin - A controlled release pharmaceutical composition which comprises therapeutically effective amount of pregabalin or salts thereof as active ingredient, a hydrophobic release controlling agent(s) and optionally other pharmaceutically acceptable excipients thereof. | 10-07-2010 |
20100240626 | ANTIEMETIC-ORAL CONTRACEPTIVE COMBINATION - The present invention relates to a method of reducing the incidence of nausea and vomiting associated with the administration of oral contraceptive formulation and a method of preparation of oral contraceptive formulation comprising progestin and/or estrogen and an antiemetic. The preferred oral contraceptive formulation comprises of levonorgestrel and an antiemetic. | 09-23-2010 |
20100160639 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE OR OPTICALLY ENRICHED ENANTIOMERS OF SULPHOXIDE COMPOUNDS - A process for preparation of optically pure or optically enriched enantiomers of sulphoxide compounds of formula (I), such as omeprazole and structurally related compounds, as well as their salts and hydrates. The said process comprises
| 06-24-2010 |
20100143471 | NOVEL REDUCED DOSE PHARMACEUTICAL COMPOSITIONS OF FEXOFENADINE AND PSEUDOEPHEDRINE - A novel reduced dose pharmaceutical composition comprising combination of fexofenadine or salts thereof; and pseudoephedrine or salts thereof in therapeutically effective amount, for the treatment of allergic rhinitis and associated symptoms in pediatric population. | 06-10-2010 |
20100105925 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE - An improved process for synthesis of duloxetine hydrochloride (1) having chiral purity greater than 99.9% that is characterized by the following:
| 04-29-2010 |
20100055181 | CONTROLLED RELEASE DOSAGE FORMS OF ZOLPIDEM - A controlled release dosage forms comprising zolpidem or a salt thereof to release zolpidem to induce rapid onset of sleep, and continue to release zolpidem in a controlled manner to maintain effective plasma concentrations over an extended period of time to improve sleep maintenance. The pharmaceutical controlled-release dosage form of zolpidem or a salt thereof having a dissolution profile when measured in a type I or II dissolution apparatus according to the U.S. Pharmacopoeia in 0.01M hydrochloric acid buffer at 37° C., such that less than 40% is released at the end of 30 minutes. | 03-04-2010 |
20100009955 | PHARMACEUTICAL COMPOSITIONS OF CEFIXIME - A pharmaceutical suspension formulation comprising a dose greater than 100 mg/5 ml Cefixime and pharmaceutically acceptable excipients. | 01-14-2010 |
20090281053 | NOVEL CRYSTALLINE FORM OF LAMIVUDINE - The disclosure herein relates to a new Lamivudine polymorphic form, methods of making the same, and pharmaceutical formulations thereof. A (−) cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one in the form of monoclinic crystals has characteristic powder X-ray diffractogram, as disclosed herein, is disclosed along with a process for preparation of the same. A pharmaceutical composition in solid dosage unit form comprising a therapeutically effective amount of a new Lamivudine polymorphic form in combination with a pharmaceutically acceptable carrier is also disclosed along with a pharmaceutical composition useful for treating HIV infections in humans. | 11-12-2009 |
20090208575 | Pharmaceutical Composition Of Acid Labile Substances - A pharmaceutical composition for oral use comprising a) a core comprising an effective amount of benzimidazole and an organic stabilizing agent which is present in an amount effective to stabilize the composition, b) an intermediate layer comprising of a water insoluble polymer and an organic stabilizer, and c) an outer enteric coating layer. The organic stabilizing agent is present in the core from about 1% to about 10% by weight of the core and in the intermediate layer from about 5% to about 35% by weight of intermediate layer. | 08-20-2009 |
20090118509 | PREPARATION OF [2-METHYL-5-PHENYL-3-(PIPERAZIN-1-YLMETHYL)] PYRROLE DERIVATIVES - A process for the preparation of compounds of Formula I and their pharmaceutically acceptable acid addition salt | 05-07-2009 |
20090082559 | Process for Crystallization of Benazepril Hydrochloride - An improved process for the crystallization of benazepril hydrochloride to obtain in at least 99.8% diastereomeric purity. The process comprises making a concentrated solution of benazepril hydrochloride in ethanol and adding the resulting solution to a non-solvent diisopropyl ether. | 03-26-2009 |
20080242676 | PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS - Novel pyrrole derivatives of formula (I) | 10-02-2008 |
20080214843 | Process for Manufacture of Simvastatin - An improved method for manufacture of simvastatin of formula (I) in high purity. The process for preparation of compound (I) comprises | 09-04-2008 |